Mackenzie Financial’s Akero Therapeutics AKRO Stock Holding History

Mackenzie Financial’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,327	Closed	-$205K	–	1670
2025 Q3	$205K	Sell	4,327 -471	-10%	-$22.8K	﹤0.01%	1557
2025 Q2	$256K	Buy	+4,798	New	+$218K	﹤0.01%	1464

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mackenzie Financial's AKRO Position: Q4 2025 in Review

Mackenzie Financial sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 4,327 shares — an estimated $205K sold.

Mackenzie Financial first reported a position in AKRO in Q2 2025 and held it in 2 quarters. The position peaked at $256K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Mackenzie Financial reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Mackenzie Financial sold 4,327 Akero Therapeutics shares in Q4 2025, an estimated $205K.
Mackenzie Financial first reported a position in Akero Therapeutics in Q2 2025 and held it in 2 quarters.
Mackenzie Financial's Akero Therapeutics position peaked at $256K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Mackenzie Financial's 13F filing for Q4 2025, filed 18 Feb 2026.